BioPlus Acquisition, a blank check company targeting life sciences, filed on Tuesday with the SEC to raise up to $220 million in an initial public offering.
The New York, NY-based company plans to raise $220 million by offering 22 million units at $10 per unit. Each unit contains one share of common stock and one-third of a warrant, exercisable at $11.50. At the proposed deal size, the company would command a market value of $281 million.
BioPlus Acquisition is led by co-CEO and CFO Ross Haghighat, founder, CEO, and Chairman of Triton Systems, and co-CEO and Director Leighton Read, Venture Partner of Alloy Ventures and Brandon Capital Ventures and founder and former CEO of biotechnology companies Avidia and Aviron. The company aims to leverage management's experience to target the life sciences industry, specifically preclinical or clinical companies with differentiated technology platforms and significant value inflection drivers in the next 18 to 24 months.
The company was founded in 2021 and plans to list on the Nasdaq under the symbol BIOS.U. BioPlus Acquisition filed confidentially on June 22, 2021. Cantor Fitzgerald is the sole bookrunner on the deal.
